Qing, Min
Zhou, Tianyuan
Perova, Tatiana
Abraham, Yann
Sweeney, Cheryl
Krevvata, Maria
Zhang, Xiaokang
Qi, Ming
Gao, Grace
Kim, Tae Min
Yao, Ming
Cho, Seok-Goo
Eom, Hyeon Seok
Lim, Soon Thye
Yeh, Su-peng
Kwong, Yok Lam
Yoon, Dok Hyun
Kim, Jin Seok
Kim, Won Seog
Zhou, Longen
Attar, Ricardo
Verona, Raluca I. http://orcid.org/0000-0003-0044-4341
Article History
Received: 15 September 2023
Accepted: 21 December 2023
First Online: 18 January 2024
Declarations
:
: The study was conducted in accordance with the principals of the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice guidelines, and the regulatory requirements at each study site. Independent ethics committees and institutional review boards at each participating site approved the study protocol and amendments. All patients provided written informed consent.
: M. Qing, T.P., Y.A., C.S., M.K., X.Z., G.G., L.Z., and R.A. are employees of Janssen and may hold equity in Janssen. T.M.K. reports a consulting or advisory role for AstraZeneca/MedImmune, Boryung, Hanmi, Janssen, Novartis, Regeneron, Roche/Genentech, Samsung Bioepis, Takeda, and Sanofi, and research funding from AstraZeneca-KHIDI outside this work. M.Y. has no conflicts to disclose. S.-G.C. reports research funding from Roche, Kyowa Kirin, Novartis, Janssen, and Celltrion and holds stock for LucasBio Co. Ltd and ViGenCell Inc. H.S.E. has no conflicts to disclose. S.T.L. has no conflicts to disclose. S.-p.Y. served as an advisory board member for AbbVie, Amgen, Janssen, Astellas, Astex, and Takeda. Y.L.K. has no conflicts to disclose. D.H.Y. reports research funding from Janssen. J.S.K. has no conflicts to disclose. W.S.K. reports research funding from Roche, Kyowa Kirin, Novartis, Janssen, Mundipharma, Celltrion, and Donga. T.Z., M. Qi, and R.I.V. were employed at Janssen at the time of the study.